Pyroptosis

ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications

Retrieved on: 
Wednesday, February 28, 2024
Pyroptosis, Liver, Macrophage, Inflammation, Cell death, ASC, Cardiovascular disease, Cancer, NLRP3, Syndrome, WAT, Breast, Dyslipidemia, Therapy, Hypertension, Super Meat Boy, Insulin resistance, Adipose tissue, Inflammasome, Tissue, DSM-IV codes, Research, Pharmaceutical industry

Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.

Key Points: 
  • Pyroptosis results in systemic release of inflammatory cytokines, IL-1β and IL-18, and ASC specks, which perpetuates and spreads inflammation to other tissues leading to the metabolic disturbances associated with obesity.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, designed to inhibit formation of multiple types of inflammasomes and their associated ASC specks to attenuate initiation and perpetuation of damaging inflammation.
  • WESTON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, highlights data published in Nature reinforcing IC 100’s rationale for inhibiting ASC and ASC Specks to attenuate damaging inflammation associated with various conditions, including obesity and its complications.
  • Likewise, IC 100 uniquely inhibits ASC specks to attenuate spread and perpetuation of damaging inflammation.” To review a white paper summarizing the mechanism of action and preclinical data for IC 100, Click Here .

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Retrieved on: 
Wednesday, December 6, 2023
Necrosis, Pyroptosis, Cholesterol, Artery, Inflammasome, Plasma, ASC, AIM2, Therapy, Inflammation, Stroke, Lipid, Animal, Patient, Plaque, Pharmaceutical industry

The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.

Key Points: 
  • The study published in Diabetes demonstrates that AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which inhibits multiple inflammasome pathways (including NLRP3 and AIM2) to attenuate initiation and perpetuation of damaging inflammation that is pathogenic in numerous diseases.
  • In the paper titled, “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” the authors studied mouse models of type 1 diabetes and atherosclerosis.
  • Results are consistent with other animal model studies showing deficiencies in essential inflammasome components, such as NLRP3, AIM2, ASC, and caspase-1, appear to protect against atherosclerosis.

ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation

Retrieved on: 
Monday, November 6, 2023
Inflammasome, Policy, Biomass, Inflammation, ASC, Kidney, NLRP3, Air pollution, Research, Journal, Security, Chronic kidney disease, Acute kidney injury, Cell death, Particulates, Kidney disease, Therapy, Super Meat Boy, Disability, Fire, Pyroptosis, Pharmaceutical industry, Vaccine, Ecotoxicology

ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.

Key Points: 
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
  • Inhibiting the inflammasome NLRP3 pathway, including downstream caspase-1, rescued the kidneys from PM2.5-induced cell death.
  • The authors stated, “We further provided evidence that NLRP3-mediated pyroptosis plays critical roles in the progression of kidney injury induced by PM2.5 exposure.
  • Inhibiting the activation of NLRP3 inflammasome can remarkably protect the renal tubular epithelial cells from PM2.5-induced proptosis.” To read the article, Click Here .

Ventus Therapeutics Presents an Overview of its NLRP3 Inhibitors at Inflammasome Therapeutics Summit

Retrieved on: 
Thursday, December 1, 2022
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, COVID-19, Inflammasome, Pain scale, Therapy, Neurology, NLRP3, Protein, Resolve, Inflammation, CNS, Pyroptosis, Multiple sclerosis, Pharmacology, Health, Rheumatism, Pharmaceutical industry, Vitro

She also provided an update on the companys brain-penetrant NLRP3 inhibitor, VENT-02, which was recently selected as Ventus second development candidate.

Key Points: 
  • She also provided an update on the companys brain-penetrant NLRP3 inhibitor, VENT-02, which was recently selected as Ventus second development candidate.
  • As Ventus second NLRP3 development candidate, it shows our belief in targeting this inflammasome to address systemic and neurological diseases, said Ms. Auger.
  • NLRP3 is a member of a family of proteins known as inflammasome receptors and is integral in the formation of the NLRP3 inflammasome.
  • Therapeutic inhibition of NLRP3 can, therefore, prevent the formation of the NLRP3 inflammasome, which in turn inhibits the production of IL-1 and IL-18.

Halia Therapeutics Presents at 4th Inflammasome Therapeutics Summit

Retrieved on: 
Thursday, December 1, 2022
Research, Diabetes, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Therapy, Patient, NLRP3, Inflammation, Pyroptosis, Multiple sclerosis, Inflammasome, Rheumatism, Immunotherapy, Vaccine, Pharmaceutical industry

Halia Therapeutics , a clinical stage biopharmaceutical company advancing innovative medicines to treat diseases driven by chronic inflammation, was invited to present today at the 4th Inflammasome Therapeutics Summit .

Key Points: 
  • Halia Therapeutics , a clinical stage biopharmaceutical company advancing innovative medicines to treat diseases driven by chronic inflammation, was invited to present today at the 4th Inflammasome Therapeutics Summit .
  • "Halia is pioneering the third wave of anti-inflammatory therapeutics, targeting the root cause of chronic inflammation," noted Dr. Bearss.
  • HT-6184 prevents the interaction of NEK7 with NLRP3, which blocks the formation of the NLRP3 inflammasome complex, an important driver of chronic inflammation.
  • Halia Therapeutics is discovering and developing novel therapeutics to improve the lives of patients with inflammatory disorders and neurological diseases.

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, General Health, Health, Pharmaceutical, Health Technology, Therapy, Inflammation, Health, Multiple sclerosis, Lists of diseases, Chronic kidney disease, COVID-19, NLRP3, NASH, Inflammasome, LinkedIn, Company, Senior, Rheumatism, Industry, Program, Patient, CEO, Protein, Fatty liver disease, Liver, Pyroptosis, Neurology, Research, Novo Nordisk, Kidney, Pain scale, Resolve, Fine chemical, Pharmaceutical industry, Ventus

Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.

Key Points: 
  • Under the terms of the agreement, Novo Nordisk will make an upfront payment of $70 million in cash to Ventus and provide research and development funding.
  • In exchange, Novo Nordisk will receive exclusive worldwide rights to develop and commercialize Ventus lead NLRP3 inhibitor program for a broad range of diseases, including nonalcoholic steatohepatitis (NASH), chronic kidney disease, and other cardiometabolic conditions.
  • In addition, Ventus retains worldwide rights to the companys distinct brain-penetrant NLRP3 inhibitor program.
  • Ventus has developed a highly differentiated NLRP3 inhibitor program with best-in-class properties and compelling pre-clinical results.

Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases

Retrieved on: 
Tuesday, August 30, 2022
Inflammation, Collagen, CEO, Program, United States Patent and Trademark Office, Symphony, Patent, Achievement, Disease, Pyroptosis, Chronic kidney disease, USPTO, CKD, NCE, TGF, Senior, Fibrosis, PALO, IPF, Risk, Lupus, Idiopathic pulmonary fibrosis, Patient, Pharmaceutical industry, Chemistry

PALO ALTO, Calif., Aug. 30, 2022 /PRNewswire/ -- Aria Pharmaceuticals, a pharmaceutical company focused on bringing first-in-class small molecules to market, announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs.

Key Points: 
  • A provisional patent application with the USPTO allows Aria Pharmaceuticals to establish intellectual property protection for its novel therapies on the filing date.
  • Aria was able to identify novel compounds and file for provisional patents within 12-15 months for each program.
  • Aria Pharmaceuticals has built a pipeline across 18 diseases utilizing its Symphony platform for complex diseases where new treatments are needed.
  • Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel small molecule therapies for complex and hard-to-treat diseases.

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

Retrieved on: 
Wednesday, June 29, 2022
FCAS, Patient, Adult, Research, MWS, GLOBE, COVID-19, Atherosclerosis, CNS, Cryopyrin-associated periodic syndrome, LFT, C-reactive protein, Membrane protein, Risk, U.S. Securities and Exchange Commission, PD, NLRP3, Q3, Inflammation, AES, Pharmacokinetics, Security (finance), Private Securities Litigation Reform Act, ATP, Doctor of Philosophy, Nasdaq, SEC, CAPS, Inflammasome, Muckle–Wells syndrome, MAD, TYK2, Safety, SAD, MD, Pyroptosis, NOMID, Neurodegeneration, Pharmaceutical industry, Vaccine, Part Two

ENCINITAS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a multi-asset, clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced positive data from the company’s Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of VTX2735, a peripheral NLRP3 inhibitor, and the first of two product candidates from its NLRP3 portfolio.

Key Points: 
  • The second candidate, VTX3232, is an orally bioavailable, CNS-penetrant NLRP3 inhibitor and belongs to a structurally distinct chemical series than VTX2735.
  • I am very excited about the progress the Ventyx team has made on our NLRP3 inhibitor portfolio and the emerging clinical profile of VTX2735, said Raju Mohan, PhD, Chief Executive Officer.
  • We look forward to sharing data from the Phase1 trial of VTX958, our oral, selective TYK2 inhibitor, in the third quarter.
  • The inclusion of forward-looking statements should not be regarded as a representation by Ventyx that any of its plans will be achieved.

Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease

Retrieved on: 
Wednesday, March 30, 2022
Treatment, Therapy, Multiple sclerosis, Lists of diseases, COO, Boston Park Plaza, Inflammation, Multimedia, Alzheimer's disease, Summit, Biotechnology, NLRP3, Parkinson's disease, CEO, SALT, Pyroptosis, Patient, Pharmaceutical industry

These small molecule therapeutics have the potential to target many systemic inflammatory and neurological disease indications.

Key Points: 
  • These small molecule therapeutics have the potential to target many systemic inflammatory and neurological disease indications.
  • Dr. Bearss' presentation was entitled, "Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer's Disease."
  • "The data and strategy presented today represent a new paradigm for targeting NLRP3.
  • Significant neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis are also driven by NLRP3 activation.

OMass Unveils Rich Drug Discovery Pipeline Targeting Intractable or Inadequately Drugged Membrane and Complex-bound Proteins

Retrieved on: 
Thursday, November 4, 2021
ACTH, Solution, Biotechnology, Technology, Mass spectrometry, Ecosystem, GPCR, Disease, Neuron, Congenital adrenal hyperplasia, IFN, Membrane protein, Adrenocorticotropic hormone, Pyroptosis, Drug discovery, Degenerative disease, Probability, Potassium, SLC15A4, Lupus, Company, G protein-coupled receptor, Computational chemistry, Therapy, GSK, University of Oxford, Enzyme, Inflammatory bowel disease, Seizure, Fine chemical, Pharmaceutical industry, Vaccine, Financial services

OMass patent-protected platform is based on ground-breaking research by Professor Dame Carol Robinson at Oxford University, who redefined mass spectrometry to enable the analysis of interactions between intact, folded proteins.

Key Points: 
  • OMass patent-protected platform is based on ground-breaking research by Professor Dame Carol Robinson at Oxford University, who redefined mass spectrometry to enable the analysis of interactions between intact, folded proteins.
  • Over the past three years, this technology has been industrialised to become OMass discovery platform.
  • OMass Therapeutics is a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes.
  • OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs.